Satsuma Pharmaceuticals, Inc. Net Income
Satsuma Pharmaceuticals, Inc. reported Net Income of -$10.29 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2023-05-11
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for the quarter ending 2023-03-31 was -$10.29M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for the quarter ending 2022-12-31 was -$23.13M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for the quarter ending 2022-09-30 was -$15.14M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for the quarter ending 2022-06-30 was -$16.27M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for fiscal 2022 was -$70.06M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for fiscal 2021 was -$51.17M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for fiscal 2020 was -$47.56M.
- Satsuma Pharmaceuticals, Inc. net income (loss) attributable to parent for fiscal 2019 was -$28.18M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$10.29M 10-Q · filed 2023-05-11 | -$33.42M derived: sum of 2 quarters · filed 2023-05-11 | -$48.56M derived: sum of 3 quarters · filed 2023-05-11 | -$64.83M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -$23.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$38.27M derived: sum of 2 quarters · filed 2023-03-28 | -$54.54M derived: sum of 3 quarters · filed 2023-03-28 | -$70.06M 10-K · filed 2023-03-28 |
| 2022-09-30 | -$15.14M 10-Q · filed 2022-11-03 | -$31.41M derived: sum of 2 quarters · filed 2022-11-03 | -$46.92M 10-Q · filed 2022-11-03 | -$62.48M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | -$16.27M 10-Q · filed 2022-11-03 | -$31.79M 10-Q · filed 2022-08-09 | -$47.34M derived: sum of 3 quarters · filed 2023-05-11 | -$60.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | -$15.52M 10-Q · filed 2023-05-11 | -$31.07M derived: sum of 2 quarters · filed 2023-05-11 | -$44.40M derived: sum of 3 quarters · filed 2023-05-11 | -$56.23M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$15.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$28.88M derived: sum of 2 quarters · filed 2023-03-28 | -$40.72M derived: sum of 3 quarters · filed 2023-03-28 | -$51.17M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$13.33M 10-Q · filed 2022-11-03 | -$25.16M derived: sum of 2 quarters · filed 2022-11-03 | -$35.62M 10-Q · filed 2022-11-03 | -$48.10M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$11.83M 10-Q · filed 2022-11-03 | -$22.29M 10-Q · filed 2022-08-09 | -$34.77M derived: sum of 3 quarters · filed 2022-11-03 | -$46.81M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | -$10.46M 10-Q · filed 2022-11-03 | -$22.93M derived: sum of 2 quarters · filed 2022-11-03 | -$34.98M derived: sum of 3 quarters · filed 2022-11-03 | -$46.25M derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | -$12.48M 10-K · filed 2021-03-25 | -$24.52M derived: sum of 2 quarters · filed 2021-11-09 | -$35.79M derived: sum of 3 quarters · filed 2021-11-09 | -$47.56M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$12.04M 10-Q · filed 2021-11-09 | -$23.31M derived: sum of 2 quarters · filed 2021-11-09 | -$35.09M 10-Q · filed 2021-11-09 | -$45.89M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$11.27M 10-Q · filed 2021-11-09 | -$23.04M 10-Q · filed 2021-08-10 | -$33.85M derived: sum of 3 quarters · filed 2021-11-09 | -$42.11M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-03-31 | -$11.77M 10-Q · filed 2021-11-09 | -$22.58M derived: sum of 2 quarters · filed 2021-11-09 | -$30.84M derived: sum of 3 quarters · filed 2021-11-09 | -$37.13M derived: sum of 4 quarters · filed 2021-11-09 |
| 2019-12-31 | -$10.81M 10-K · filed 2021-03-25 | -$19.07M derived: sum of 2 quarters · filed 2021-03-25 | -$25.36M derived: sum of 3 quarters · filed 2021-03-25 | -$28.18M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$8.26M 10-K · filed 2021-03-25 | -$14.55M derived: sum of 2 quarters · filed 2021-03-25 | -$17.37M 10-Q · filed 2020-11-10 | -$19.71M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | -$6.29M 10-K · filed 2021-03-25 | -$9.11M 10-Q · filed 2020-08-11 | -$11.45M derived: sum of 3 quarters · filed 2021-03-25 | -$13.04M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | -$2.81M 10-K · filed 2021-03-25 | -$5.16M derived: sum of 2 quarters · filed 2021-03-25 | -$6.75M derived: sum of 3 quarters · filed 2021-03-25 | -$8.95M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | -$2.34M 10-K · filed 2020-03-10 | -$3.93M derived: sum of 2 quarters · filed 2020-03-10 | -$6.13M derived: sum of 3 quarters · filed 2020-03-10 | -$7.35M 10-K · filed 2020-03-10 |
| 2018-09-30 | -$1.59M 10-K · filed 2020-03-10 | -$3.79M derived: sum of 2 quarters · filed 2020-03-10 | -$5.00M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$2.20M 10-K · filed 2020-03-10 | -$3.42M 10-Q · filed 2019-11-12 | ||
| 2018-03-31 | -$1.21M 10-K · filed 2020-03-10 | |||
| 2017-12-31 | -$5.17M 10-K · filed 2020-03-10 |